<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Navamedic Asa — News on 6ix</title>
<link>https://6ix.com/company/navamedic-asa-1</link>
<description>Latest news and press releases for Navamedic Asa on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Oct 2025 06:24:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/navamedic-asa-1" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d55039beedb30cb6f78748.webp</url>
<title>Navamedic Asa</title>
<link>https://6ix.com/company/navamedic-asa-1</link>
</image>
<item>
<title>Navamedic ASA: Double digit growth in the 3rd quarter, 2025</title>
<link>https://6ix.com/company/navamedic-asa-1/news/navamedic-asa-double-digit-growth-in-the-3rd-quarter-2025</link>
<guid isPermaLink="true">https://6ix.com/company/navamedic-asa-1/news/navamedic-asa-double-digit-growth-in-the-3rd-quarter-2025</guid>
<pubDate>Tue, 28 Oct 2025 06:24:00 GMT</pubDate>
<description>In the third quarter 2025, Navamedic ASA (OSE: NAVA), a Nordic pharma company and trusted supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies, delivered revenues of NOK 138.9 million, a 12.9% increase from the third quarter in 2024. Gross margin improved to 37.5 per cent, compared to 37.1 per cent in Q3 2024 and Adjusted EBITDA amounted to NOK 11.3 million compared to NOK 8.6 million in 2024.</description>
</item>
<item>
<title>Navamedic ASA: Financial report for the 2nd quarter and first half of 2025</title>
<link>https://6ix.com/company/navamedic-asa-1/news/navamedic-asa-financial-report-for-the-2nd-quarter-and-first-half-of-2025</link>
<guid isPermaLink="true">https://6ix.com/company/navamedic-asa-1/news/navamedic-asa-financial-report-for-the-2nd-quarter-and-first-half-of-2025</guid>
<pubDate>Thu, 14 Aug 2025 05:32:00 GMT</pubDate>
<description>In the first half of 2025, Navamedic ASA (OSE: NAVA), a Nordic pharma company and trusted supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies, delivered revenues of NOK 269.3 million, down from NOK 277.2 million in 2024. Excluding the milestone license fee from Orion corporation of NOK 22.7 million in 2024, revenues grew by 5.8 per cent YoY, gross margin improved to 37.3 per cent, compared to 37.0 per cent in Q2 2024 and EBITDA amounted to NO</description>
</item>
<item>
<title>Navamedic ASA: National approvals of Flexilev® in OraFID® granted across all Nordic countries</title>
<link>https://6ix.com/company/navamedic-asa-1/news/navamedic-asa-national-approvals-of-flexilevr-in-orafidr-granted-across-all-nordic-countries</link>
<guid isPermaLink="true">https://6ix.com/company/navamedic-asa-1/news/navamedic-asa-national-approvals-of-flexilevr-in-orafidr-granted-across-all-nordic-countries</guid>
<pubDate>Wed, 13 Aug 2025 08:07:00 GMT</pubDate>
<description>Navamedic is pleased to announce that it has received final approval for the packaging material in national languages for Norway, Sweden and Denmark, following the earlier announcement on June 27th. Orion Corporation ("Orion"), the product licensor for Finland and the rest of the EU, has also obtained final confirmation for the Finnish market.</description>
</item>
<item>
<title>Navamedic ASA: Closing of the transaction to acquire the business of dne pharma</title>
<link>https://6ix.com/company/navamedic-asa-1/news/navamedic-asa-closing-of-the-transaction-to-acquire-the-business-of-dne-pharma</link>
<guid isPermaLink="true">https://6ix.com/company/navamedic-asa-1/news/navamedic-asa-closing-of-the-transaction-to-acquire-the-business-of-dne-pharma</guid>
<pubDate>Tue, 15 Jul 2025 10:49:00 GMT</pubDate>
<description>Reference is made to the stock exchange announcement published by Navamedic ASA ("Navamedic" or the "Company", OSE ticker: "NAVA") on 23 June 2025, regarding Navamedic entering into an asset purchase agreement for the acquisition of the business of dne pharma AS for a total consideration of up to NOK 225 million, whereby NOK 185 million is payable at closing, and the remaining NOK 40 million is payable in two tranches subject to achievement of certain agreed sales volumes for the acquired produc</description>
</item>
<item>
<title>Navamedic ASA - Minutes of Extraordinary General Meeting</title>
<link>https://6ix.com/company/navamedic-asa-1/news/navamedic-asa-minutes-of-extraordinary-general-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/navamedic-asa-1/news/navamedic-asa-minutes-of-extraordinary-general-meeting</guid>
<pubDate>Mon, 14 Jul 2025 13:37:00 GMT</pubDate>
<description>The announced Extraordinary General Meeting of Navamedic ASA was held today at 13.00 CET. All items on the agenda were approved in accordance with the board of directors' proposals. A copy of the minutes from the EGM is attached to this notice and will also be made available on the Company's webpage www.navamedic.com.</description>
</item>
<item>
<title>Navamedic ASA: First approval of the medical device OraFID® as primary package for a pharmaceutical product</title>
<link>https://6ix.com/company/navamedic-asa-1/news/navamedic-asa-first-approval-of-the-medical-device-orafidr-as-primary-package-for-a-pharmaceutical-product</link>
<guid isPermaLink="true">https://6ix.com/company/navamedic-asa-1/news/navamedic-asa-first-approval-of-the-medical-device-orafidr-as-primary-package-for-a-pharmaceutical-product</guid>
<pubDate>Fri, 27 Jun 2025 12:30:00 GMT</pubDate>
<description>Navamedic announces that the Swedish Medical Products Agency, acting as the Reference Member State, together with the Concerned Member States in 9 additional countries have approved OraFID® for use with a medicinal product.</description>
</item>
<item>
<title>Navamedic ASA - Investor presentation regarding the acquisition of the business of dne pharma AS</title>
<link>https://6ix.com/company/navamedic-asa-1/news/navamedic-asa-investor-presentation-regarding-the-acquisition-of-the-business-of-dne-pharma-as</link>
<guid isPermaLink="true">https://6ix.com/company/navamedic-asa-1/news/navamedic-asa-investor-presentation-regarding-the-acquisition-of-the-business-of-dne-pharma-as</guid>
<pubDate>Tue, 24 Jun 2025 06:21:00 GMT</pubDate>
<description>Reference is made to the announcement made by Navamedic ASA (the "Company" or "Navamedic", and OSE ticker "NAVA") yesterday, on June 23, regarding Navamedic entering into an asset purchase agreement for the acquisition of the business of dne pharma AS.</description>
</item>
<item>
<title>Navamedic ASA expands into addiction treatment through the acquisition of the business of dne pharma and announces a partially underwritten rights issue</title>
<link>https://6ix.com/company/navamedic-asa-1/news/navamedic-asa-expands-into-addiction-treatment-through-the-acquisition-of-the-business-of-dne-pharma-and-announces-a-partially-underwritten-rights-issue</link>
<guid isPermaLink="true">https://6ix.com/company/navamedic-asa-1/news/navamedic-asa-expands-into-addiction-treatment-through-the-acquisition-of-the-business-of-dne-pharma-and-announces-a-partially-underwritten-rights-issue</guid>
<pubDate>Mon, 23 Jun 2025 06:14:00 GMT</pubDate>
<description>Navamedic ASA (OSE: NAVA) ("Navamedic" or the "Company"), a Nordic pharmaceutical company and trusted supplier of high-quality products to hospitals and pharmacies, has today entered into an agreement to acquire the business of dne pharma as ("dne pharma") for a total consideration of up to NOK 225 million (the "Acquisition"). The purchase price is payable in instalments, whereby NOK 185 million is payable at closing of the Acquisition, and the remaining NOK 40 million is payable in two tranches</description>
</item>
<item>
<title>Navamedic ASA: Annual Report 2024</title>
<link>https://6ix.com/company/navamedic-asa-1/news/navamedic-asa-annual-report-2024</link>
<guid isPermaLink="true">https://6ix.com/company/navamedic-asa-1/news/navamedic-asa-annual-report-2024</guid>
<pubDate>Wed, 30 Apr 2025 17:53:00 GMT</pubDate>
<description>Navamedic ASA has today published its Annual Report for 2024. Find enclosed the report in PDF as well as an ESEF file version. The report is also made available at the company's website at https://navamedic.com/investors/annual-reports/</description>
</item>
<item>
<title>Navamedic ASA: Imdur® distribution agreement extended to 2032</title>
<link>https://6ix.com/company/navamedic-asa-1/news/navamedic-asa-imdurr-distribution-agreement-extended-to-2032</link>
<guid isPermaLink="true">https://6ix.com/company/navamedic-asa-1/news/navamedic-asa-imdurr-distribution-agreement-extended-to-2032</guid>
<pubDate>Tue, 29 Apr 2025 15:49:00 GMT</pubDate>
<description>Navamedic ASA (OSE: NAVA) today announced it has signed a renewed distribution agreement with TopRidge Pharma Limited (TopRidge) for Imdur®, valid until June 2032, including options for new products to be added to the agreement.</description>
</item>
</channel>
</rss>